<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83323">
  <stage>Registered</stage>
  <submitdate>4/11/2008</submitdate>
  <approvaldate>5/08/2011</approvaldate>
  <actrnumber>ACTRN12611000830998</actrnumber>
  <trial_identification>
    <studytitle>A double-blind, randomised, placebo-controlled study to evaluate the effect of an orally-dosed herbal formulation containing Testofen, on sexual function, performance, and serum testosterone levels in healthy males.</studytitle>
    <scientifictitle>A double-blind, randomised, placebo-controlled study to evaluate the effect of an orally-dosed herbal formulation containing Testofen, on sexual function, performance, and serum testosterone levels in healthy males.</scientifictitle>
    <utrn />
    <trialacronym>TFN-SFN08</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Sexual performance</healthcondition>
    <healthcondition>Sexual function</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Tablet-form herbal formulation containing Trigonella foenum-graecum seed extract (equivalent to 9900 mg), magnesium aspartate (equivalent to Mg 15.17 mg), zinc amino acid chelate (equivalent to Zn 15 mg) and vitamin B6 (equivalent to pyridoxine 4.94 mg).

Dosing is one tablet, twice per day, by-mouth: one hour before the morning meal (breakfast) and one hour before the evening meal (dinner) for a total of 2 tablets per day, for the duration of the trial (6 weeks).</interventions>
    <comparator>Placebo tablet containing rice bran, cellulose-microcrystalline, and calcium hydrogen phosphate, croscarmellose sodium, crospovidone, povidone, ethylcellulose, iron oxide, hypromellose, silicon dioxide, magnesium stearate, and coating (opadry II and carnuba wax). This control tablet is dosed as per the investigational product.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Derogatis Interview for Sexual Functioning - Self Report - Male (DISF-SR Male) total score. The DISF-SR (Male) questionnaire is completed by the participant.</outcome>
      <timepoint>Pre-intervention (during the week prior to intervention) and at the end of weeks 2, 4, and 6 (on the last day of each week) during intervention.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum testosterone, determined by laboratory serum analysis.</outcome>
      <timepoint>Blood collection will occur at pre-intervention (within the week prior to intervention) and completion of intervention (during the last two days of intervention).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum prolactin, determined by laboratory serum analysis.</outcome>
      <timepoint>Blood collection will occur at pre-intervention (within the week prior to intervention) and completion of intervention (during the last two days of intervention).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum prostate specific antigen (PSA), determined by laboratory serum analysis.</outcome>
      <timepoint>Blood collection will occur at pre-intervention (within the week prior to intervention) and completion of intervention (during the last two days of intervention).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>DISF-SR (male) domain subscores: sexual cognition/fantasy; sexual arousal; sexual behaviour/experiences; and orgasm. The DISF-SR (Male) questionnaire is completed by the participant.</outcome>
      <timepoint>As per the primary outcome: pre-intervention (during the week prior to intervention) and at the end of weeks 2, 4, and 6 (on the last day of each week) during intervention.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>General libido improvement. The participant will be asked a global efficacy question ("Do you feel that the medication you have been taking for the last six weeks improved your libido?").</outcome>
      <timepoint>During the exit interview, which is conducted during the week subsequent to conclusion of intervention.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Heterosexual; Stable sexual relationship for at least the last 6 months; Sexually active for at least the last 6 months; Anticipated stable sexual relationship for at least the next 8 weeks; Sexual partner willing to provide information during interviews; Written informed consent from the subject.</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Homosexual orientation; Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion; Known hypersensitivity to herbal drugs/nutritional supplement/ foods; Possible physical unavailability of sexual partner during trial period; Any physical disability that may limit sexual function; Received any treatment/therapy for any sexual disorder during last 6 months; Receiving/ prescribed coumadin (Warfarin), heparin, daltaparin, enoxaparin or other anticoagulation therapy; Receiving/ prescribed levodopa (Sinemet)  for Parkinsons Disease or calcipotriene (Dovonex) for Psoriasis; Diagnosed with hypertension and receiving/ prescribed antihypertensive medications; Diagnosed severe renal and/or hepatic insufficiency; Diagnosed genital anatomical deformities, uncontrolled diabetes mellitus, and history of spinal cord injury, uncontrolled psychiatric disorder, and/or abnormal secondary sexual characteristics; Diagnosed prostatic cancer or benign hypertrophy; if suspected by the investigator, refer for medical assessment; Acute genitourinary disorder; History of genital surgery; Current or history of chronic alcohol and/or drug abuse; Suspected or diagnosed chickpea allergy; Participation in any other clinical trial during last 30 days; Simultaneous participation in another clinical trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>2/01/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AZPA International</primarysponsorname>
    <primarysponsoraddress>17 Concord Drive
Keilor Park VIC 3042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>AZPA International</fundingname>
      <fundingaddress>17 Concord Drive
Keilor Park VIC 3042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Totally Natural Products</sponsorname>
      <sponsoraddress>13-14 Durian Place
Wetherill Park NSW 2164</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial is being undertaken to assess whether the herbal formulation containing Testofen improves general sexual function, performance, and satisfaction in healthy males.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Queensland Clinical Trial Network (QCTN)</ethicname>
      <ethicaddress />
      <ethicapprovaldate>13/10/2008</ethicapprovaldate>
      <hrec>HREC-001</hrec>
      <ethicsubmitdate>8/09/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Beth Steels</name>
      <address>PO Box 68
New Farm QLD 4005</address>
      <phone>+61 7 3162 0909</phone>
      <fax />
      <email>beth@asnresearch.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Amanda Rao</name>
      <address>PO Box 68
New Farm QLD 4005</address>
      <phone>+61 7 3162 0909</phone>
      <fax />
      <email>info@asnresearch.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Amanda Rao</name>
      <address>PO Box 68
New Farm QLD 4005</address>
      <phone>+61 7 3162 0909</phone>
      <fax />
      <email>amanda@asnresearch.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>